IDiyas

For the Inventor, By the Inventor

Gauting, Germany

Patrick A Baeuerle

USPTO Granted Patents = 35 

 

Average Co-Inventor Count = 4.1

ph-index = 10

Forward Citations = 302(Granted Patents)


Location History:

  • Munich, DE (2007 - 2014)
  • Cambridge, MA (US) (2019)
  • South San Francisco, CA (US) (2003 - 2022)
  • Gauting, DE (2001 - 2024)

Company Filing History:

goldMedal9 out of 9 
 
Tcr2 Therapeutics Inc.
 patents
silverMedal7 out of 10 
 
Werewolf Therapeutics, Inc.
 patents
bronzeMedal6 out of 23 
 
Harpoon Therapeutics, Inc.
 patents
4. 5 out of 25 
 
Micromet Ag
 patents
5. 2 out of 75 
 
Amgen Research (munich) Gmbh
 patents
6. 2 out of 1,970 
 
Amgen Inc.
 patents
7. 1 out of 1 
 
Tcr2 Therabeutics Inc.
 patent
8. 1 out of 126 
 
Tularik Limited
 patents
9. 1 out of 1,177 
 
Takeda Pharmaceutical Company Limited
 patents
10. 1 out of 832,680 
Other
 patents

Years Active: 2001-2025

Loading Chart...
Loading Chart...
35 patents (USPTO):
1. 12275769 - Activatable interleukin 12 polypeptides and methods of use thereof (2025-04-14),
2. 12128102 - Constrained conditionally activated binding proteins (2024-10-29),
3. 12084518 - Trispecific binding proteins and methods of use (2024-09-10),
4. 11981716 - Activatable interleukin-2 polypeptides and methods of use thereof (2024-05-14),
5. 11965012 - Compositions and methods for TCR reprogramming using fusion proteins (2024-04-23),
6. 11851491 - Compositions and methods for TCR reprogramming using fusion proteins (2023-12-26),
7. 11753475 - Bispecific-Fc molecules (2023-09-12),
8. 11535668 - Inducible monovalent antigen binding protein (2022-12-27),
9. 11535658 - Activatable interleukin-2 polypeptides and methods of use thereof (2022-12-27),
10. 11453710 - Activatable interleukin 12 polypeptides and methods of use thereof (2022-09-27),
11. 11377638 - Compositions and methods for TCR reprogramming using fusion proteins (2022-07-05),
12. 11352403 - Activatable interleukin-2 polypeptides and methods of use thereof (2022-06-07),
13. 11242376 - Compositions and methods for TCR reprogramming using fusion proteins (2022-02-08),
14. 11154617 - Means and methods for the treament of B cell non-hodgkin lymphoma and B cell leukemia (2021-10-26),
15. 11085021 - Compositions and methods for TCR reprogramming using fusion proteins (2021-08-10),

Title: The Innovative Journey of Patrick A. Baeuerle

Introduction: Patrick A. Baeuerle is a renowned inventor hailing from Gauting, Germany, known for his groundbreaking contributions to the field of biotechnology and pharmaceuticals.

Latest Patents: Patrick A. Baeuerle holds several patents in the areas of immunotherapy, cancer treatment, and targeted therapies, showcasing his commitment to advancing medical science through innovation.

Career Highlights: With a distinguished career spanning over three decades, Baeuerle has held key positions in various research institutions and biotech companies, leading teams in the development of novel therapies for complex diseases.

Collaborations: Throughout his career, Patrick A. Baeuerle has collaborated with leading scientists, researchers, and pharmaceutical companies worldwide, fostering a culture of innovation and knowledge exchange in the scientific community.

Conclusion: Patrick A. Baeuerle's relentless pursuit of innovation and his passion for improving patient outcomes have solidified his reputation as a pioneering inventor in the field of biotechnology, leaving a lasting impact on the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…